Thermostable vaccines can reduce dependence on continuous refrigeration during last-mile distribution and vaccination campaigns.
Controlled temperature chain use allows approved vaccines to remain above standard refrigerated conditions for a defined, monitored period.
MenAfriVac demonstrates how product-specific temperature flexibility can support remote delivery without eliminating oversight.
Spray drying, lyophilization, sugar films, and microneedle patches are expanding the range of vaccine stabilization strategies.
Thermostability targets should reflect the intended distribution environment, dosage form, storage duration, and regulatory claim.
Why Vaccine Access Depends on Temperature Flexibility
Vaccines are only as deployable as the systems that preserve them. A product may be clinically effective, manufacturable at scale, and suitable for broad immunization yet still remain difficult to distribute if it depends on uninterrupted temperature control through every warehouse, vehicle, clinic, and outreach site. Refrigeration protects product quality, but it also shapes where vaccination can occur, how frequently supplies must be delivered, and which facilities can participate.1,2
Thermostability offers a way to loosen some of those constraints, but the term can obscure as much as it clarifies. It may describe a vaccine approved for a few days outside standard refrigeration, a product that remains stable for months at elevated temperatures, or an experimental formulation that retains activity after a defined heat challenge. These are distinct achievements with different implications for manufacturing, labeling, logistics, and use.3–5
The breadth of this spectrum also affects how innovation should be judged. A vaccine does not need to remain stable indefinitely at very high temperatures to produce a meaningful improvement. A modest, validated extension may be enough to reach sites without refrigerators, reduce dependence on daily transport, or make campaign planning more flexible. Conversely, an impressive laboratory heat challenge may have little immediate operational effect if it has not been connected to a final presentation, clinical evidence, approved labeling, and a realistic distribution model.1,6
The most practical objective is not to eliminate the cold chain in every circumstance. It is to create product-specific temperature flexibility where that flexibility can improve access, reduce operational burden, or protect doses from foreseeable distribution risks. The strongest examples combine formulation science with clear monitoring requirements, clinical evidence, and an intended use case.
The Cold Chain Is Both Essential and Constraining
Cold-chain management is often framed as protection against heat, but temperature control also has to prevent accidental freezing. Vaccines can encounter subzero temperatures during transport or storage when ice packs, refrigerators, or handling practices push products outside their approved range. A temperature-monitoring initiative in Tunisia found that continuous monitoring and targeted freeze-prevention measures significantly reduced inadvertent exposure to freezing conditions.7
The safest system is therefore not simply the coldest system. It is one that keeps a product within its validated range throughout distribution. That task becomes more difficult as vaccines move away from centralized storage and toward remote facilities, mobile teams, and temporary campaign sites. Limited refrigerated capacity and limited ice-pack-freezing capacity have both been identified as constraints during vaccination campaigns, especially when large volumes must move quickly through the final stages of distribution.1
The operational burden is unevenly distributed. Well-equipped urban facilities may absorb refrigeration requirements with relatively little disruption, while smaller or more remote sites may depend on frequent deliveries, limited storage, or tightly scheduled outreach sessions. In a series of interviews, stakeholders in six low- and middle-income countries (LMICs) identified improved vaccine stability and controlled temperature chain labeling as potentially useful tools for addressing these pressures.2
Thermostability therefore must be evaluated against a specific bottleneck. A product that can remain outside refrigeration for several days may be especially useful for outreach or campaign delivery. A vaccine with a longer refrigerated shelf life presents a different operating profile, while a dry formulation that tolerates ambient storage could create another set of distribution options. The value depends on where the existing temperature requirement limits access or complicates execution.
The target should also reflect the stage at which temperature exposure is most difficult to manage. Long-term storage at a central warehouse, transport between regional facilities, storage at a local clinic, and carriage to an outreach site impose different demands. A single product may still rely on refrigeration for most of its life cycle while gaining substantial value from a limited period of controlled exposure near the point of administration. Defining that sequence early gives stability studies a clearer purpose and helps distinguish essential product requirements from desirable but less consequential improvements.
Defining Thermostability More Precisely
A controlled temperature chain (CTC) provides the clearest example of how temperature flexibility can be formalized. Under this model, a vaccine may be kept above its standard long-term storage range of +2 °C to +8 °C for a limited period under defined, monitored conditions. To qualify for CTC use under current criteria, a vaccine must tolerate at least 40 °C for at least three days, and the authorized conditions must appear in the approved labeling.3
Monitoring remains central to this approach. Each vial must carry a vaccine vial monitor (VVM), and each vaccine carrier must include a peak-temperature indicator. A VVM responds to cumulative heat exposure and indicates when a vial has crossed the predetermined threshold beyond which it should no longer be used.3,8
CTC use is a regulated extension of the permitted operating window, not unrestricted ambient storage. The distinction is important because the word “thermostable” is often applied across very different levels of evidence. A product with an approved CTC label has completed a different path from a preclinical vaccine that retains activity after short-term exposure to elevated temperature. Likewise, a formulation that remains stable for months at 37 °C supports a different claim from one that is stable for six months at 2–8 °C.
Temperature, duration, dosage form, development stage, and intended use all determine what a stability result means. The relevant question is not simply whether a vaccine is heat stable, but what conditions it can tolerate, for how long, in which presentation, and with what supporting evidence. This framework allows developers and public health programs to compare products without collapsing distinct achievements into a single category.
MenAfriVac as the Field-Proven CTC Model
MenAfriVac, a safe, low-cost conjugate vaccine created to prevent group A meningococcal meningitis in sub-Saharan Africa, shows how a defined stability profile can translate into a practical distribution strategy. In 2012, the vaccine’s license was changed to permit one period of CTC use lasting up to four days at temperatures up to 40 °C.1 The significance of that change lay in the final segment of distribution, where limited refrigeration and ice-pack capacity could complicate campaign execution.
The revised conditions did not remove MenAfriVac from controlled storage altogether. They created a specific period during which the vaccine could be carried and administered outside the conventional refrigerated range, provided that the approved conditions and monitoring requirements were followed. This gave vaccination teams more flexibility without replacing regulatory oversight with informal handling.
Field evidence supported the safety of the approach. In Benin, adverse events during the first five days after vaccination were no more frequent among recipients whose vaccine had been delivered through CTC than among those receiving vaccine through the conventional cold chain or in previously reported clinical trial settings.9
The economic evidence was more context dependent. During a campaign in Togo, average logistics costs were estimated at $0.026 per dose for facilities using CTC and $0.029 per dose for facilities using the full cold chain, a difference that was not statistically significant. However, the same analysis estimated that daily deliveries to facilities without refrigerators would have increased average logistics costs to $0.063 per dose, with the largest increases at more remote facilities.6
These findings do not support a universal claim that CTC always lowers costs. They show that its value increases when conventional refrigeration creates a disproportionate burden. Remote facilities, sites without refrigerators, and programs that would otherwise require repeated daily deliveries stand to gain more than locations already supported by reliable cold-chain infrastructure.
MenAfriVac also demonstrates why thermostability must be translated into an operating model. Stability data alone did not create the access benefit. The effect depended on a licensed temperature window, clear handling conditions, monitoring tools, and a campaign design able to use that flexibility. The product, label, and distribution strategy had to function together.
Heat-Stable Vaccines Beyond Short-Term CTC Use
ROTASIIL illustrates a different thermostability profile. The lyophilized live attenuated rotavirus vaccine remained stable at 37 °C and 40 °C for more than six months, extending well beyond the short-duration flexibility associated with CTC use.4
The clinical evidence addressed a separate but equally important question. In a randomized, placebo-controlled trial in Niger, 3,508 infants were included in the per-protocol analysis, and three doses provided 66.7% efficacy against severe rotavirus gastroenteritis. Overall adverse events and serious adverse events did not differ significantly between the vaccine and placebo groups.10
Stability and clinical performance are related, but neither substitutes for the other. A heat-stable formulation must still demonstrate that it produces the intended clinical outcome, while an effective vaccine must retain its required quality through the storage and distribution conditions proposed for use. The connection between those evidence streams supports a product claim that is both scientifically and operationally meaningful.
ROTASIIL also shows why thermostable should not be treated as shorthand for a single distribution category. Stability for more than six months at elevated temperatures is materially different from a four-day CTC window, even though both can improve delivery. Each profile addresses different constraints and requires different assumptions about inventory, transport, storage, and campaign planning.
Drying Technologies as a Route to Greater Stability
Many vaccine-stabilization strategies focus on the dry state. Removing water and embedding the active material in a stabilizing matrix can change how a product responds to heat, although the result depends heavily on the antigen, excipients, process, and final presentation.
Spray drying has produced encouraging results across several vaccine types. In one pilot-scale study, spray-dried hepatitis B vaccine formulations remained stable for at least 24 months at 37 °C, while several meningitis A vaccine formulations remained stable at temperatures up to 60 °C.11 These findings show that a glassy-state formulation can achieve substantial thermal tolerance, but they do not by themselves establish a commercial shelf life or an approved distribution condition.
A separate study used spray drying to stabilize a vesicular stomatitis virus (VSV)-vectored vaccine. After 15 days at 37 °C, the dried vaccine retained in vivo immunogenicity, while the corresponding liquid control lost its immune-stimulating activity.5 The comparison illustrates how strongly physical presentation can influence thermal performance, even when the underlying vector remains the same.
Sugar-film approaches offer another route. A pullulan–trehalose matrix provided thermal protection for experimental herpes simplex virus type 2 and influenza A virus preparations.12 Here again, the formulation method altered the response to temperature stress, but the work remained experimental and specific to the tested systems.
These technologies should not be grouped together simply because they produce a dry product. Spray-dried powders, lyophilized cakes, and sugar films impose different stresses during manufacture and create different final presentations and development requirements. The excipient system that protects one antigen or viral vector may not protect another, and combination products may introduce additional compatibility challenges.
The manufacturing implications begin early. Drying conditions, formulation composition, and final presentation must be developed as an integrated system. A successful laboratory result also has to survive scale-up without losing the physical or biological attributes responsible for stability. The available evidence does not support a single preferred process, but it does show that process selection can materially reshape the temperature profile of a vaccine candidate.
Microneedle Patches Combine Stability and Delivery
Microneedle patches extend the dry-state concept by combining formulation and administration in a single product presentation. Work on measles–rubella vaccination shows how this approach can move from screening and stabilization into clinical evaluation.
During formulation development for a dried measles–rubella vaccine intended for the Nanopatch system, eight candidate formulations met the target of less than a 1-log₁₀ potency loss after one week at 37 °C. Leading candidates later showed less than a 0.1-log₁₀ measles titer loss and approximately a 0.4-log₁₀ rubella titer loss after six months at 2–8 °C compared with frozen controls.13
Separate work demonstrated the thermostability of a bivalent measles–rubella vaccine in a microneedle patch and found that rubella stability required pH buffering during drying.14 The result is important because it shows that even closely linked components within the same combination vaccine may have different stabilization needs. A formulation that protects measles potency may not automatically provide equivalent protection for rubella.
The clinical program in the Gambia added comparative human data. Among initially measles-seronegative infants, 93% of those vaccinated by microneedle patch seroconverted, compared with 90% of those receiving subcutaneous vaccination. Rubella seroconversion reached 100% in both groups, and no related severe or serious adverse events were reported.15
The microneedle approach therefore involves more than transferring a conventional vaccine into a new container. The relevant product includes the antigen combination, excipients, drying process, patch architecture, and delivery method. Stability has to be demonstrated in the final presentation, and clinical evaluation has to address the performance of that presentation as administered.
This integrated development model may be especially important for combination vaccines, where each component can respond differently to processing and storage. The measles–rubella program shows that a delivery innovation can advance alongside thermostability, but it also shows why formulation work must remain specific to the product rather than generalized across a platform.
Extending Thermostability to RNA Vaccines
RNA vaccines present a compound stability challenge because both the RNA and its delivery system must retain the properties needed for biological activity. Lyophilization has emerged as one route for widening the temperature window of these products.
In one study of a lyophilized messenger RNA–lipid nanoparticle (mRNA–LNP) vaccine, the formulation retained 75.6% relative mRNA integrity after 60 days at 40 °C.16 This result demonstrates that the temperature sensitivity often associated with RNA products can be altered through formulation and processing, although it remains specific to the tested construct and delivery system.
A separate preclinical program developed lyophilized self-replicating RNA vaccines for COVID-19 and malaria. The COVID-19 candidate underwent six-month storage studies at 2–8 °C and 25 °C, with stability and immunogenicity included in the evaluation.17
These studies do not establish that RNA vaccines as a class can move outside cold-chain controls. They show that storage requirements arise from the full product design rather than from modality alone. RNA sequence, delivery vehicle, lyoprotectants, drying process, and final dosage form all contribute to the resulting stability profile.
The same caution applied earlier remains relevant here. Accelerated or preclinical storage data demonstrate technical potential, but they do not automatically support a licensed shelf life, a CTC designation, or routine ambient distribution. The value of these studies lies in showing that formulation engineering can expand the design space for RNA vaccines and may allow future products to target more practical storage conditions.
What Thermostability Changes for Vaccine Development
Thermostability is most useful when it is defined as a target product attribute rather than a general aspiration. Development teams need to specify the temperature range, duration, dosage form, and stage of distribution where flexibility would create the greatest value. A vaccine intended for a four-day outreach campaign requires a different profile from one designed for months of regional storage or repeated shipment through varied infrastructure.
The evidence across MenAfriVac, ROTASIIL, dried viral vaccines, microneedle patches, and RNA formulations shows that several development elements have to align. The formulation must protect the active material under the proposed conditions. The manufacturing process must consistently produce the physical state responsible for that protection. The final presentation must preserve stability through storage and handling. Clinical evidence must support the performance of the product as used, and labeling must translate the demonstrated temperature window into clear operating conditions.
Monitoring remains part of the design even as temperature tolerance improves. CTC use depends on approved conditions, VVMs, and peak-temperature indicators because a wider window still has boundaries.3,8 A product that tolerates more heat may reduce the risk associated with some excursions, but it still requires a reliable way to distinguish acceptable exposure from unacceptable exposure.
The studies also show why accelerated stability data must be interpreted carefully. A short period at a high temperature can help identify formulation differences or demonstrate resilience, but it does not automatically predict a commercial shelf life. Likewise, a refrigerated stability result cannot be translated into an ambient-storage claim without supporting evidence. Each condition answers a specific development question.
Combination products add another layer. The measles–rubella patch work showed that different antigens within the same product can require different stabilization approaches.13,14 RNA systems add the requirement to protect both nucleic acid and delivery vehicle.16,17 Drying technologies can improve stability, but they also introduce process-specific stresses that must be controlled.
For vaccine developers and manufacturing partners, the clearest path is to begin with the intended distribution environment. The formulation strategy can then be built around a defined use case rather than an abstract goal of maximum heat resistance. That approach helps prevent overengineering in settings where a modest extension would be sufficient and underengineering where ambient or elevated-temperature storage is central to access.
Matching Stability to Global Access Needs
The public health value of thermostability depends on whether the resulting product profile addresses a real distribution barrier. LMIC stakeholders saw improved stability and CTC labeling as potentially useful responses to cold-chain challenges, but their relevance varied with local infrastructure and operating conditions.2
The MenAfriVac experience provides a concrete example. A four-day window at temperatures up to 40 °C could support campaign delivery in settings where refrigeration, ice-pack production, or repeated daily transport created logistical pressure.1 In Togo, the strongest economic advantage appeared at more remote facilities that would otherwise have required daily deliveries.6
Other use cases may require different solutions. Extended refrigerated stability may be sufficient for one distribution model. Room-temperature storage may matter most for products moving through limited infrastructure. A dried patch may align stability with a new delivery format, while a lyophilized RNA formulation may make a platform more adaptable to varied distribution environments.
Global access will depend less on whether every vaccine becomes completely independent of refrigeration and more on whether each product gains the flexibility needed for its intended route to patients. The useful endpoint is a validated temperature profile that removes a specific barrier without creating ambiguity about product quality or handling.
Conclusion
Thermostable vaccines span a continuum of capabilities, from limited CTC use to prolonged stability at elevated temperatures and experimental dry-state formulations. MenAfriVac shows how a narrowly defined temperature window can improve campaign flexibility when it is supported by labeling, monitoring, and field implementation. ROTASIIL connects long-duration heat stability with clinical efficacy and safety evidence. Spray drying, sugar films, microneedle patches, and lyophilized RNA systems show how formulation and presentation may broaden future options.
Each advance must still be interpreted according to its temperature, duration, dosage form, development stage, monitoring requirements, and regulatory status. The most valuable stability profile is not necessarily the most extreme one. It is the profile that solves a defined distribution problem while preserving product quality, clinical performance, and control.
